Sugi Predict

Sugi Predict / Compounds / SCHEMBL9997448

SCHEMBL9997448

SCHEMBL9997448

Nc1ccc(-c2cc(S(=O)(=O)Nc3ccc(C(=O)O)c(O)c3)sc2Cl)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PFKFB3 Q16875 8/20 0.69
▸ HSD17B10 Q99714 3/20 0.49
▸ HPGD P15428 2/20 0.49
▸ ACLY P53396 2/20 0.46
▸ ALDH1A1 P00352 4/20 0.46
▸ MCL1 Q07820 1/20 0.43
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ USP2 O75604 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ MAPT P10636 2/20 0.41
▸ GAA P10253 2/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ ESR2 Q92731 1/20 0.41
▸ PTPN1 P18031 1/20 0.41
▸ POLB P06746 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ CSNK2A2 P19784 1/20 0.39
▸ CSNK2B P67870 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9997307 0.91 PFKFB3 (0.72) PFKFB3HSD17B10HPGDACLYALDH1A1
SCHEMBL9997089 0.90 PFKFB3 (0.70) PFKFB3HSD17B10HPGDACLYALDH1A1
SCHEMBL9997122 0.90 PFKFB3 (0.67) PFKFB3HSD17B10HPGDACLYALDH1A1
SCHEMBL9997140 0.89 PFKFB3 (0.69) PFKFB3HSD17B10HPGDACLYALDH1A1
SCHEMBL9996826 0.89 PFKFB3 (0.69) PFKFB3HSD17B10HPGDACLYALDH1A1
SCHEMBL9997581 0.88 PFKFB3 (0.68) PFKFB3HSD17B10HPGDACLYALDH1A1
SCHEMBL9997256 0.87 PFKFB3 (0.66) PFKFB3HSD17B10HPGDACLYALDH1A1
SCHEMBL9997332 0.85 PFKFB3 (0.70) PFKFB3HSD17B10HPGDACLYALDH1A1
SCHEMBL9997211 0.85 PFKFB3 (0.67) PFKFB3HSD17B10HPGDACLYALDH1A1
SCHEMBL9997444 0.85 PFKFB3 (0.67) PFKFB3HSD17B10HPGDACLYALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011161201-A1 BISARYLSULFONAMIDES USEFUL AS KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2011-12-29 — — WO claimed
US-20230047816-A1 PFKFB3 INHIBITORS AND THEIR USES GERO PTE. LTD. (SG) 2023-02-16 — — US disclosed
CN-113396145-A PFKFB3 inhibitors and uses thereof 盖罗发现有限责任公司 2021-09-14 — — CN disclosed
WO-2020080979-A1 PFKFB3 INHIBITORS AND THEIR USES GERO DISCOVERY LIMITED LIABILITY COMPANY (RU) 2020-04-23 — — WO disclosed
WO-2011161201-A1 BISARYLSULFONAMIDES USEFUL AS KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2011-12-29 — — WO disclosed
WO-2011161201-A1 BISARYLSULFONAMIDES USEFUL AS KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2011-12-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230047816-A1 PFKFB3 INHIBITORS AND THEIR USES PFKFB3, PFKFB4, PFKFB1 PFKFB3 1/4885HSD17B10 1255/4885HPGD 980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.